2014
The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients
Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O’Connor P, Weiss L, Fiellin DA, Fiellin LE. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug And Alcohol Dependence 2014, 139: 79-85. PMID: 24726429, PMCID: PMC4029496, DOI: 10.1016/j.drugalcdep.2014.03.006.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentOpioid-dependent patientsHIV risk behaviorsBuprenorphine/naloxoneNon-condom useNaloxone treatmentRisk behaviorsTreatment initiationViral loadHIV-1 RNA viral loadCocaine/amphetaminesTime-updated variablesRNA viral loadMajor risk factorOpioid-dependent populationsCochran-Armitage trend testSexual risk behaviorsOlder patientsHIV infectionOpioid dependenceRisk factorsHeroin useHIVPatientsTargeted interventions
2007
Primary Care Office-based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients
Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O’Connor P, Schottenfeld RS. Primary Care Office-based Buprenorphine Treatment: Comparison of Heroin and Prescription Opioid Dependent Patients. Journal Of General Internal Medicine 2007, 22: 527-530. PMID: 17372805, PMCID: PMC1829433, DOI: 10.1007/s11606-007-0129-0.Peer-Reviewed Original ResearchConceptsPrescription opioid useOpioid useOnly patientsPrescription opioidsTreatment outcomesBuprenorphine/naloxone maintenanceBuprenorphine/naloxone treatmentOpioid-negative urine samplesPrescription opioid-dependent patientsHepatitis C antibodyDrug treatment historyOpioid-dependent patientsPrimary care officesOffice-based settingClinical characteristicsBuprenorphine treatmentNaloxone treatmentBuprenorphine/Opioid dependenceCare officesDependent patientsTreatment responseC antibodyHeroin usePatients
2000
Pharmacologic treatment of heroin-dependent patients.
O'Connor P, Fiellin D. Pharmacologic treatment of heroin-dependent patients. Annals Of Internal Medicine 2000, 133: 40-54. PMID: 10877739, DOI: 10.7326/0003-4819-133-1-200007040-00008.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHeroin dependenceHeroin-dependent patientsDrug treatment settingsBehavioral health problemsOpioid withdrawalPharmacologic treatmentMethadone maintenanceHeroin usePhysician's officeTreatment approachesTreatment settingsHealth problemsPatientsRelapse preventionTreatmentPhysiciansAcetylmethadolBuprenorphineInternistsReferralDiagnosisAlternative sitesPrevention
1999
Plasma concentrations of buprenorphine 24 to 72 hours after dosing
Chawarski MC, Schottenfeld RS, O’Connor P, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug And Alcohol Dependence 1999, 55: 157-163. PMID: 10402160, DOI: 10.1016/s0376-8716(98)00192-6.Peer-Reviewed Original ResearchConceptsDose scheduleWithdrawal symptomsPlasma concentrationsDaily buprenorphine doseHigh-dose scheduleThrice-weekly scheduleAdministration of buprenorphineOpiate-dependent subjectsHigher plasma concentrationsUse of heroinBuprenorphine doseDaily administrationOutpatient clinicPlasma levelsSublingual administrationAgonist effectsOpiate useHeroin useLow doseHigh doseBuprenorphine solutionMg/70High dosesConcentration 24Dependent subjects
1995
Primary care-based ambulatory opioid detoxification
O’Connor P, Waugh M, Carroll K, Rounsaville B, Diagkogiannis I, Schottenfeld R. Primary care-based ambulatory opioid detoxification. Journal Of General Internal Medicine 1995, 10: 255-260. PMID: 7616334, DOI: 10.1007/bf02599882.Peer-Reviewed Original ResearchConceptsInjection drug usersClonidine/naltrexoneOpioid detoxificationDrug treatmentProspective nonrandomized clinical trialMedical clinicsPrimary care medical clinicFirst heroin useOngoing drug treatmentNonrandomized clinical trialPrimary care providersWithdrawal symptom scoresSubstance abuse treatmentMuscle crampsSymptom scoresClinical trialsClonidineNurse practitionersCare providersDetoxified patientsHeroin useTreatment groupsNaltrexoneDrug usersMedical units